Enveric Biosciences, INC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Enveric Biosciences, Inc. common stock.

A filing reveals Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri collectively hold a 2.93% stake in Enveric Biosciences, Inc. through warrant exercises.

Lind Global Fund III LP and associated parties have filed a Schedule 13G reporting a 7.87% beneficial ownership stake in Enveric Biosciences, Inc. through warrant holdings.

Lind Global Fund III LP and affiliates reported a 9.99% passive beneficial ownership stake in Enveric Biosciences, Inc., including common stock and warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Enveric Biosciences, Inc. common stock.

AdvisorShares Trust has reported a 1.66% beneficial ownership stake in Enveric Biosciences, Inc., holding 16,974 shares of common stock.

Intracoastal Capital, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 4.99% beneficial ownership stake in Enveric Biosciences, Inc. via a Schedule 13G filing.

Braeden Lichti and Northstrive Fund II LP have filed an amendment to their Schedule 13G, indicating they are no longer beneficial owners of Enveric Biosciences, Inc. common stock.

Northstrive Fund II LP and Braeden Lichti have filed an amendment to their Schedule 13G, indicating they no longer beneficially own shares of Enveric Biosciences, Inc. as of December 9, 2025.

Braeden Lichti and Northstrive Fund II LP have disclosed a combined beneficial ownership of 5.01% in Enveric Biosciences, Inc. common stock.

Northstrive Fund II LP and Braeden Lichti have disclosed a combined beneficial ownership of 5.01% of Enveric Biosciences, Inc.'s common stock.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Enveric Biosciences, Inc., primarily through common stock and warrants.

AdvisorShares Trust has reported a 6.27% beneficial ownership stake in Enveric Biosciences, Inc., holding 203,679 shares of common stock.

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 0.4% beneficial ownership stake in Enveric Biosciences, Inc. as of September 24, 2025.

AdvisorShares Trust has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.65% in Enveric Biosciences, Inc. as of March 31, 2025.

A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a passive beneficial ownership of 4.99% in Enveric Biosciences, Inc. common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Enveric Biosciences, Inc. as of January 31, 2025.

Orca Capital AG has filed a Schedule 13G, reporting beneficial ownership of 8.7% of Enveric Biosciences, Inc.'s common stock as of January 30, 2025.

AdvisorShares Trust has filed a Schedule 13G, reporting a passive beneficial ownership of 5.9% in Enveric Biosciences, Inc.'s common stock as of December 31, 2024.